688197 首药控股-U
已收盘 10-30 15:00:00
资讯
新帖
简况
首药控股(688197)9月30日股东户数0.65万户，较上期增加10.31%
证券之星 · 10-28
首药控股(688197)9月30日股东户数0.65万户，较上期增加10.31%
首药控股（688197）10月23日主力资金净买入266.11万元
证券之星 · 10-24
首药控股（688197）10月23日主力资金净买入266.11万元
首药控股（688197）10月21日主力资金净买入773.67万元
证券之星 · 10-22
首药控股（688197）10月21日主力资金净买入773.67万元
首药控股（688197）10月12日主力资金净买入17.39万元
证券之星 · 10-13
首药控股（688197）10月12日主力资金净买入17.39万元
首药控股（688197）8471.45万股限售股将于10月12日解禁，占总股本56.96%
证券之星 · 10-12
首药控股（688197）8471.45万股限售股将于10月12日解禁，占总股本56.96%
首药控股（688197）10月8日主力资金净卖出77.22万元
证券之星 · 10-09
首药控股（688197）10月8日主力资金净卖出77.22万元
首药控股（688197）9月24日主力资金净卖出696.41万元
证券之星 · 09-25
首药控股（688197）9月24日主力资金净卖出696.41万元
首药控股（688197）披露首次公开发行限售股份上市流通提示性公告，9月23日股价上涨0.97%
证券之星 · 09-23
首药控股（688197）披露首次公开发行限售股份上市流通提示性公告，9月23日股价上涨0.97%
每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市
证券之星 · 08-30
每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市
首药控股（688197）披露签订《施工总承包合同》暨对外投资进展公告，8月26日股价下跌1.1%
证券之星 · 08-26
首药控股（688197）披露签订《施工总承包合同》暨对外投资进展公告，8月26日股价下跌1.1%
每周股票复盘：首药控股（688197）变更持续督导保荐代表人
证券之星 · 08-09
每周股票复盘：首药控股（688197）变更持续督导保荐代表人
首药控股（688197）披露关于变更持续督导保荐代表人的公告，8月4日股价上涨1.07%
证券之星 · 08-04
首药控股（688197）披露关于变更持续督导保荐代表人的公告，8月4日股价上涨1.07%
每周股票复盘：首药控股（688197）获第四代ALK抑制剂临床试验批件
证券之星 · 07-19
每周股票复盘：首药控股（688197）获第四代ALK抑制剂临床试验批件
首药控股(688197.SH)：第四代ALK抑制剂SY-12321获得药物临床试验批准通知书
智通财经 · 07-16
首药控股(688197.SH)：第四代ALK抑制剂SY-12321获得药物临床试验批准通知书
每周股票复盘：首药控股（688197）完成工商变更拓展药品经营业务
证券之星 · 07-12
每周股票复盘：首药控股（688197）完成工商变更拓展药品经营业务
异动快报：首药控股-U（688197）7月6日10点14分触及涨停板
证券之星 · 07-06
异动快报：首药控股-U（688197）7月6日10点14分触及涨停板
每周股票复盘：首药控股（688197）召开2025年年度股东会
证券之星 · 06-28
每周股票复盘：首药控股（688197）召开2025年年度股东会
首药控股（688197）披露2025年年度股东会决议公告，6月26日股价下跌3.7%
证券之星 · 06-26
首药控股（688197）披露2025年年度股东会决议公告，6月26日股价下跌3.7%
首药控股(688197.SH)：ALK抑制剂康特替尼颗粒获批上市
智通财经 · 06-11
首药控股(688197.SH)：ALK抑制剂康特替尼颗粒获批上市
每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势
证券之星 · 05-17
每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势
公司概况
公司名称：
首药控股(北京)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-23
主营业务：
首药控股(北京)股份有限公司的主营业务是肿瘤领域创新小分子疗法的发现与开发。公司的主要产品是SY-707（康特替尼颗粒）。
发行价格：
39.90
{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股-U","latestPrice":32.4,"timestamp":1793343600000,"preClose":32.79,"halted":0,"volume":2175349,"delay":0,"changeRate":-0.0119,"floatShares":149000000,"shares":149000000,"eps":-0.1252,"marketStatus":"已收盘","change":-0.39,"latestTime":"10-30 15:00:00","open":32.51,"high":34.86,"low":31.38,"amount":71730100,"amplitude":0.1061,"askPrice":32.41,"askSize":3,"bidPrice":32.4,"bidSize":7,"shortable":0,"etf":0,"ttmEps":-0.1252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":32.79,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":36.07,"lowLimit":29.51,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"isCdr":false,"pbRate":7.58,"roa":"--","roe":"--","epsLYR":-0.87,"committee":-0.435374,"marketValue":4819000000,"turnoverRate":0.0146,"status":1,"afterMarket":{"amount":0,"volume":0,"close":32.4,"buyVolume":0,"sellVolume":3500,"time":1793345637746,"indexStatus":"已收盘 10-30 15:30:00","preClose":32.79},"floatMarketCap":4819000000},"requestUrl":"/m/hq/s/688197/wiki","defaultTab":"wiki","newsList":[{"id":"2678463270","title":"首药控股(688197)9月30日股东户数0.65万户，较上期增加10.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678463270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678463270?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:33","pubTimestamp":1793183631,"startTime":"0","endTime":"0","summary":"证券之星消息，近日首药控股披露，截至2026年9月30日公司股东户数为6527.0户，较6月30日增加610.0户，增幅为10.31%。在化学制药行业个股中，首药控股股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.9万户。从股价来看，2026年6月30日至2026年9月30日，首药控股区间涨幅为12.84%，在此期间股东户数增加610.0户，增幅为10.31%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800040221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677790330","title":"首药控股（688197）10月23日主力资金净买入266.11万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677790330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677790330?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:13","pubTimestamp":1792800839,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，首药控股报收于35.75元，上涨7.94%，换手率2.09%，成交量3.11万手，成交额1.07亿元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入469.77万元，融资偿还447.51万元，融资净买入22.26万元。首药控股主营业务：肿瘤领域创新小分子疗法的发现与开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677986552","title":"首药控股（688197）10月21日主力资金净买入773.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677986552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677986552?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:17","pubTimestamp":1792628277,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月21日收盘，首药控股报收于33.44元，上涨3.31%，换手率0.94%，成交量1.39万手，成交额4622.08万元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入248.32万元，融资偿还274.1万元，融资净偿还25.79万元。首药控股主营业务：肿瘤领域创新小分子疗法的发现与开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200006700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675386180","title":"首药控股（688197）10月12日主力资金净买入17.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675386180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675386180?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:33","pubTimestamp":1791851619,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月12日收盘，首药控股报收于33.8元，下跌4.82%，换手率1.23%，成交量1.82万手，成交额6282.35万元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入290.45万元，融资偿还236.67万元，融资净买入53.78万元。首药控股主营业务：肿瘤领域创新小分子疗法的发现与开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300007208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674084476","title":"首药控股（688197）8471.45万股限售股将于10月12日解禁，占总股本56.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674084476","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674084476?lang=zh_cn&edition=full","pubTime":"2026-10-12 08:02","pubTimestamp":1791763335,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，首药控股于10月12日将有8471.45万股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本56.96%。首药控股主营业务：肿瘤领域创新小分子疗法的发现与开发。本文数据来源于首药控股公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674889548","title":"首药控股（688197）10月8日主力资金净卖出77.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889548","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674889548?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:27","pubTimestamp":1791505654,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，首药控股报收于34.75元，下跌7.82%，换手率4.96%，成交量3.18万手，成交额1.13亿元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入872.3万元，融资偿还335.72万元，融资净买入536.58万元。首药控股主营业务：肿瘤领域创新小分子疗法的发现与开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670246419","title":"首药控股（688197）9月24日主力资金净卖出696.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670246419","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670246419?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:28","pubTimestamp":1790296128,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，首药控股报收于37.72元，下跌4.41%，换手率4.44%，成交量2.84万手，成交额1.09亿元。近5日资金流向一览见下表：首药控股融资融券信息显示，融资方面，当日融资买入744.86万元，融资偿还444.56万元，融资净买入300.31万元，连续3日净买入累计547.9万元。首药控股主营业务：肿瘤领域创新小分子疗法的发现与开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669484918","title":"首药控股（688197）披露首次公开发行限售股份上市流通提示性公告，9月23日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669484918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669484918?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:25","pubTimestamp":1790173520,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，首药控股报收于39.46元，较前一交易日上涨0.97%，最新总市值为58.68亿元。近日，首药控股（北京）股份有限公司发布《关于首次公开发行限售股份上市流通的提示性公告》。公告显示，公司首次公开发行限售股份将于2026年10月12日上市流通，本次解除限售股份数量为84,714,461股，占公司总股本的56.9626%。上述股东已履行股份锁定承诺，锁定期已届满。股份解除限售后，相关股东将遵守减持相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663004513","title":"每周股票复盘：康特替尼获批，首药控股（688197）首款创新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2663004513","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663004513?lang=zh_cn&edition=full","pubTime":"2026-08-30 10:13","pubTimestamp":1788055988,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，首药控股报收于34.94元，较上周的37.71元下跌7.35%。本周，首药控股8月24日盘中最高价报38.45元。股本股东变化截至2026年6月30日，公司股东户数为5917.0户，较3月31日增加328.0户，增幅5.87%。户均持股数量由上期的2.66万股降至2.51万股，户均持股市值为83.97万元。公司持续推进“提质增效重回报”行动方案，进入研发与商业化协同推进新阶段，经营亏损大幅收窄，财务结构稳健，募集资金使用规范。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0239","688197","BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662183718","title":"首药控股（688197）披露签订《施工总承包合同》暨对外投资进展公告，8月26日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662183718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662183718?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:52","pubTimestamp":1787741566,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，首药控股报收于35.22元，较前一交易日下跌1.1%，最新总市值为52.38亿元。首药控股（北京）股份有限公司于近日披露《关于签订〈施工总承包合同〉暨对外投资的进展公告》。公告显示，公司于2026年8月25日与杭萧钢构（河北）建设有限公司正式签订《施工总承包合同》，合同金额为人民币38,916.87万元（含税），用于建设“首药控股新药研发与产业化基地项目”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600042651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673675","title":"每周股票复盘：首药控股（688197）变更持续督导保荐代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673675?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:49","pubTimestamp":1786214949,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，首药控股报收于36.2元，较上周的32.26元上涨12.21%。本周，首药控股8月7日盘中最高价报36.25元。本周关注点公司公告汇总：首药控股变更持续督导保荐代表人，王辉接替杨慧泽履行督导职责。公司公告汇总首药控股（北京）股份有限公司发布公告，因原持续督导保荐代表人杨慧泽先生工作调动，中信建投证券指派王辉先生接替其职务，继续履行公司首次公开发行股票并在科创板上市项目的持续督导职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552288","title":"首药控股（688197）披露关于变更持续督导保荐代表人的公告，8月4日股价上涨1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552288?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:33","pubTimestamp":1785853993,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，首药控股报收于32.14元，较前一交易日上涨1.07%，最新总市值为47.8亿元。该股当日开盘31.8元，最高33.18元，最低31.8元，成交额达6516.55万元，换手率为3.14%。近日，首药控股（北京）股份有限公司发布公告称，因原持续督导保荐代表人杨慧泽先生工作调动，中信建投证券指派王辉先生接替其职务，继续履行公司首次公开发行股票并在科创板上市项目的持续督导职责。变更后，持续督导保荐代表人为王辉先生和李彦芝女士。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652230754","title":"每周股票复盘：首药控股（688197）获第四代ALK抑制剂临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2652230754","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652230754?lang=zh_cn&edition=full","pubTime":"2026-07-19 03:12","pubTimestamp":1784401931,"startTime":"0","endTime":"0","summary":"本周，首药控股7月15日盘中最高价报45.95元。本周关注点公司公告汇总：首药控股获第四代ALK抑制剂SY-12321临床试验批准，拟用于解决三代ALK抑制剂耐药问题。公司公告汇总首药控股（北京）股份有限公司自愿披露，公司自主研发的第四代ALK抑制剂SY-12321胶囊获国家药监局核准签发的《药物临床试验批准通知书》，同意开展针对ALK阳性晚期实体瘤的临床试验。目前，国内尚无第四代ALK抑制剂获批上市或进入临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900001098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651141761","title":"首药控股(688197.SH)：第四代ALK抑制剂SY-12321获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2651141761","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651141761?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:40","pubTimestamp":1784191217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。SY-12321是公司完全自主研发的化学药品1类创新药，属于第四代小分子ALK抑制剂，是公司完善ALK阳性肿瘤全生命周期治疗布局的重要候选产品，拟重点解决第三代ALK抑制剂治疗后的耐药问题，特别是ALK复合突变介导的耐药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4503","IBBQ","688197","BK0239","BK4500","BK4563","XTN","BMED","BK4008","BK4077","BK4585","SY","ALK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154311","title":"每周股票复盘：首药控股（688197）完成工商变更拓展药品经营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154311","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650154311?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:06","pubTimestamp":1783793172,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，首药控股报收于41.09元，较上周的37.5元上涨9.57%。本周，首药控股7月6日盘中最高价报45.0元。本周关注点公司公告汇总：首药控股完成工商变更，新增药品生产、零售、批发及进出口等经营范围。公司公告汇总首药控股（北京）股份有限公司于2026年4月16日和6月26日分别召开第二届董事会第十三次会议及2025年年度股东会，审议通过增加经营范围、修订《公司章程》并办理工商变更登记的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617282","title":"异动快报：首药控股-U（688197）7月6日10点14分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649617282?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:20","pubTimestamp":1783304438,"startTime":"0","endTime":"0","summary":"证券之星7月6日盘中消息，10点14分首药控股-U（688197）触及涨停板。其所属行业化学制药目前上涨。领涨股为首药控股。该股为创新药，医药概念热股，当日创新药概念上涨2.82%，医药概念上涨1.87%。7月3日的资金流向数据方面，主力资金净流出3.49万元，占总成交额0.05%，游资资金净流出141.33万元，占总成交额1.87%，散户资金净流入144.82万元，占总成交额1.92%。近5日资金流向一览见下表：首药控股-U主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600006370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646031658","title":"每周股票复盘：首药控股（688197）召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2646031658","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646031658?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:08","pubTimestamp":1782590892,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，首药控股报收于31.2元，较上周的32.38元下跌3.64%。本周关注点公司公告汇总：首药控股于2026年6月26日召开2025年年度股东会，审议通过多项议案。公司公告汇总北京市竞天公诚律师事务所对首药控股（北京）股份有限公司2025年年度股东会的召集和召开程序、出席会议人员资格、召集人资格、表决程序和表决结果等事项出具法律意见书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646666243","title":"首药控股（688197）披露2025年年度股东会决议公告，6月26日股价下跌3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646666243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646666243?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:03","pubTimestamp":1782486203,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，首药控股报收于31.2元，较前一交易日下跌3.7%，最新总市值为46.4亿元。该股当日开盘32.0元，最高33.03元，最低31.06元，成交额达4263.09万元，换手率为2.09%。近日，首药控股（北京）股份有限公司发布《2025年年度股东会决议公告》。表决程序符合法律规定，北京市竞天公诚律师事务所出具了法律意见书，确认会议召集、召开及表决合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600046210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642583402","title":"首药控股(688197.SH)：ALK抑制剂康特替尼颗粒获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642583402","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642583402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:40","pubTimestamp":1781163619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司近日通过国家药品监督管理局网站获悉，国家药品监督管理局批准公司完全自主研发的1类创新药康特替尼颗粒(CT-707，商品名：首要泽®)上市，该产品单药适用于既往未经过间变性淋巴瘤激酶(ALK)抑制剂治疗的ALK阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0239","688197","BK4500","BK4008","BK4585","ALK","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636062419","title":"每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062419","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636062419?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:53","pubTimestamp":1778964786,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，首药控股报收于41.74元，较上周的41.64元上涨0.24%。本周，首药控股5月11日盘中最高价报44.92元。答：感谢您对SY-5007的关注。上述结果表明,SY-5007在初治及经治RET融合阳性NSCLC患者中均展现出较高水平的抗肿瘤活性,并具有良好的缓解持续性趋势。在安全性方面,SY-5007整体耐受性良好。截至目前,SY-5007是临床进展最快的完全国产的选择性RET抑制剂之一,进度优势明显。这将进一步拓展SY-5007的适应症人群,扩大其市场空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793576500478,"stockEarnings":[{"period":"1week","weight":-0.0937},{"period":"1month","weight":-0.1406},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.2069},{"period":"1year","weight":-0.1728},{"period":"ytd","weight":-0.0674}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6527人(较上一季度增加10.31%)","perCapita":"22785股","listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢19层1单元2202-2号","registeredCapital":"14871万元","survey":" 首药控股(北京)股份有限公司的主营业务是肿瘤领域创新小分子疗法的发现与开发。公司的主要产品是SY-707（康特替尼颗粒）。","listedPrice":39.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股-U(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股-U(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股-U,688197,首药控股-U股票,首药控股-U股票老虎,首药控股-U股票老虎国际,首药控股-U行情,首药控股-U股票行情,首药控股-U股价,首药控股-U股市,首药控股-U股票价格,首药控股-U股票交易,首药控股-U股票购买,首药控股-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股-U(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股-U(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}